Skip to content
OpenCapital
Get started

IDEX IEX Health & Science Technologies — Segment Adjusted EBITDA

Similar metrics at other companies

International Flavors & Fragrances logo
IFFHealth & Biosciences — Segment Adjusted Operating EBITDA
$153M+10.9%
IR
IRPrecision and Science Technologies — Segment Adjusted EBITDA
$121.9M+14.8%
Clarivate logo
CLVTLife Sciences & Healthcare — Adjusted EBITDA
$29.2M-4.6%
International Flavors & Fragrances logo
IFFHealth & Biosciences — Adjusted Operating EBITDA
$153M+10.9%
SelectQuote logo
SLQTHealthcare Services — Adjusted Segment EBITDA
$5.28M-18.1%
Radiant Logistics logo
RLGTSegment Adjusted Ebitda
$10.58M-12.7%

Other financials

Income statement

See full
Revenue$886.9M+8.9%
Gross profit$398.1M+7.9%
Operating income$172.4M+21.4%
Net income$120.0M+25.7%
EPS (diluted)$1.61+27.8%

Balance sheet

See full
Cash & equivalents$591.8M-3.3%
Total debt$1.9B-3.4%
Total equity$4.0B+3.7%
Total assets$6.9B+1.8%

Cash flow

See full
Operating cash flow$103.7M-1.9%
CapEx$17.7M+23.8%
Free cash flow$86.0M-5.9%

Valuation

See full
Market cap$16.55B+18.1%
Enterprise value$17.86B+16.6%
P/E32.6×+2.8×
P/S4.7×+0.5×

Profitability

See full
Gross margin44.4%0.0pp
Operating margin20.7%+0.6pp
Net margin14.4%-0.2pp
FCF margin17.3%+0.3pp

Returns & leverage

See full
Return on equity12.8%0.0pp
Debt / equity0.5×0.0×
Current ratio3.4×+0.6×

Where this comes from

Reported directly by IDEX in its filing.

Tagged under the XBRL concept iex:AdjustedEarningsBeforeInterestTaxesDepreciationAmortization.

The official record: IDEX’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEX's health & science technologies — segment adjusted ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEX's health & science technologies — segment adjusted EBITDA?
IDEX (IEX) reported health & science technologies — segment adjusted EBITDA of $106M in Q1 2026.
How has IDEX's health & science technologies — segment adjusted EBITDA changed year-over-year?
IDEX's health & science technologies — segment adjusted EBITDA increased by 21.3% year-over-year, from $87.4M to $106M.
What is the long-term trend for IDEX's health & science technologies — segment adjusted EBITDA?
Over 4 years (2021 to 2025), IDEX's health & science technologies — segment adjusted EBITDA has grown at a 2.8% compound annual growth rate (CAGR), from $355.9M to $397.8M.
What does health & science technologies — segment adjusted EBITDA mean?
Measures the operational profitability of the Health and Science Technologies segment by adding back depreciation, amortization, and other non-recurring items to segment operating income. It serves as a key indicator of the segment's cash-generating capability before capital structure and tax considerations.